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time-lapse, on-chip imaging platform†
Chao Han* and Changhuei Yang
The observation of viral plaques is the standardmethod for determining the viral titer and understanding the
behaviors of viruses. Here, we report the application of a wide ﬁeld-of-view (FOV), time-lapse, on-chip
imaging platform, termed the ePetri, for plaque analysis of murine norovirus 1 (MNV-1). The ePetri
oﬀers the ability to dynamically track plaques at the individual cell death event level over a wide FOV of
6 mm  4 mm. As demonstration, we captured high-resolution time-lapse images of MNV-1-infected
cells at 30 min intervals. We implemented a customized image-processing program containing a
density-based clustering algorithm to analyze the spatial-temporal distribution of cell death events to
identify plaques at their earliest stages. By using the results in a viral titer count format, we showed that
our approach gives results that are comparable to conventional plaque assays. We further showed that
the extra information collected by the ePetri can be used to monitor the dynamics of plaque formation
and growth. Finally, we performed a demonstration experiment to show the relevance of such an
experimental format for viral inhibitor study. We believe the ePetri is a simple and compact solution for
the automation of viral plaque assays, plaque behavior analysis, and antiviral drug discovery and study.Introduction
The analysis of viral plaques is the standard method for deter-
mining the virus concentration and understanding their
proliferation and spread behaviors.1,2 A plaque is a region of
host cells undergoing cytopathic eﬀects (CPEs). Plaque growth
is initiated when a virus particle attaches to a host cell, pene-
trates the cell membrane, replicates, induces CPEs, and releases
a new generation of viruses, which then diﬀuse to neighboring
host cells to repeat the process.3 Because each plaque originates
from a single virus particle, the number of plaques can be
counted to determine the virus titer in a sample. This method is
termed a plaque assay, and is widely used for viral quantica-
tion.1,4 The area and shape of the plaques, together with the
speed of plaque growth, can be used to study viral behavior.5
Viral plaques can also be used for the screening of antiviral
drugs.6
Since the establishment of the rst plaque assay,4 little has
changed over the decades. Viral plaques are still grown in
conventional Petri dishes or multi-well plates. Plaques are
counted by the naked eye; therefore, several days are required
for suﬃcient growth of the plaques.1 This manual counting
process is labor-intensive and time-consuming. The plates also
have to be taken out of the incubator for observation, which isf Technology, Pasadena, CA 91125, USA.
5-3786
tion (ESI) available. See DOI:
hemistry 2014inconvenient and may disturb virus distribution. In addition,
the cells need to be stained with dyes such as neutral red or
crystal violet to enhance contrast for the plaque readout, pre-
venting continuous monitoring of plaque growth dynamics.
In recent years, studies have used standard microscopes for
time-lapse imaging of viral plaques in order to investigate the
behaviors of diﬀerent viruses. Wodarz et al. monitored the
spatial dynamics of recombinant adenovirus type-5 prolifera-
tion using a uorescence microscope.7 However, they had a
large imaging interval (24 h), and had to capture several images
for each plaque and stitch them together due to the small eld-
of-view (FOV) of the microscope. Doceul et al. studied the rapid
plaque growth of Vaccinia virus using a microscope integrated
with a stage incubator that collected time-lapse images at much
shorter intervals (1 h);2 however, they were also restricted by a
10 objective FOV, so a limited number of plaques were
recorded for statistical build-up. In summary, standard micro-
scopes are of high-cost with limited FOVs; therefore, they are
not ideal platforms for viral plaque analysis.
Commercialized systems such as the aCOLyte 3 and
ProtoCOL 3 from Synbiosis were developed for wide FOV colony
counting. They used light-emitting diodes (LEDs) for illumina-
tion, a charge-coupled device (CCD) camera with a lens for
imaging, and integrated soware capable of automated plaque
counting from Petri dishes or multi-well plates. However, they
have limited resolution (e.g., ProtoCOL 3 can accurately
measure features down to 0.1 mm) and cannot support the
observation of single cell death events. They do not provide a
cell culture environment and are not designed for continuousAnalyst, 2014, 139, 3727–3734 | 3727
Fig. 1 The ePetri device setup. (a) The ePetri device prototype. (b)
Image sensor with reservoir. (c1–c3) Viral infection and plaque growth
on the image sensor. (d) A representative, full ﬁeld-of-view, high-
resolution image with (e) a typical growing plaque zoomed in.
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View Article Onlineplaque growth monitoring. Similar to the conventional manual
plaque counting method, the sample usually has to be stained
with dyes to provide better contrast for the automatic plaque
counting soware. A technology that combines the resolution of
a microscope with the large FOV of a commercialized colony
counting system, and supports time-lapse imaging is strongly
needed.
We recently developed a wide-FOV, on-chip imaging method
termed ePetri and have demonstrated its compact, wide-FOV
imaging capability in longitudinal monitoring of cell culture
and stem cell diﬀerentiation.8 This technique is based on the
use of a super-resolution algorithm9 in combination with
proximal cell imaging by growing the cells directly on the sensor
chip to perform high-resolution and wide-FOV imaging. If the
resolution of the image is restricted by the detector pixel size, we
can enhance it by capturing a sequence of sub-pixel-shied,
low-resolution (LR) images and combining them to reconstruct
a high-resolution (HR) image. The ePetri device has demon-
strated the ability to image at 700 nm resolution with a FOV of
6 mm  4 mm without using any optical lenses.
In this study, we developed the ePetri device for use with viral
plaque assays, as well as for monitoring the dynamics of viral
plaque formation and development. We chose murine nor-
ovirus 1 (MNV-1) as our model virus and RAW 264.7 as the host
cell line. During the on-chip plaque growth we obtained a
24 mm2 FOV and time-lapse HR images at 30 min intervals. We
then built an image-processing program for plaque recognition
and tracking. We observed that cells undergoing CPEs would
detach from the substrate, becoming spherical, which focuses
more light onto the sensor surface, causing them to appear
much brighter than healthy cells. Taking advantage of this
eﬀect, we were able to segment dying cells from healthy cells
using a simple thresholding method. We also noticed that a
plaque is a cluster of high-density cell death events, so we
incorporated a well-established, density-based clustering algo-
rithm10 to detect the plaques. To our knowledge, this is the rst
time a clustering algorithm has been used for viral plaque
detection. The last step of the program distinguishes between
connected plaques by tracking their growth history. Using this
program we conducted a plaque assay, tracked plaque growth,
and studied viral inhibitors.
In the next section, we will describe the ePetri device setup
in detail and explain the imaging approach. Next we will
explain our customized plaque recognition program. We will
demonstrate the plaque counting performance of our system
in comparison with conventional plaque assays. Then, we will
show the dynamic monitoring of plaque formation and
growth. Finally, we will describe the demonstration of our
system to investigate the responses of viral plaque growth to
two diﬀerent viral inhibitors: 20-C-methylcytidine (2CMC) and
neuraminidase.
Results
Imaging principles and system setup
When the sample is on the surface of a complementary metal-
oxide semiconductor (CMOS) image sensor, it can directly3728 | Analyst, 2014, 139, 3727–3734record a shadow image of the sample. However, due to the pixel
size of the image sensor (2.2 mm in our experiment), the reso-
lution is limited to approximately twice the pixel size (according
to the Nyquist criterion). To improve the pixel-limited resolu-
tion, we applied a super-resolution algorithm described in our
previous work.8,9 Briey, we placed the sample 1 mm above the
image sensor surface (determined by the sensor's passivation
layer), then tilted the illumination angle to induce a sub-pixel
shi of the sample shadow on the image sensor, and captured a
series of LR images at each angle. Next, we calculated the
amount of the shi by estimating the height of the sample
above the pixels. Finally, we interpolated the LR images into a
larger matrix according to their corresponding shi amounts, to
reconstruct a HR image.
The ePetri device is depicted in Fig. 1a. It consists of (1) an
illuminator, (2) a CMOS sensor chip with a reservoir (also shown
in Fig. 1b), (3) a camera board, and (4) a thermoelectric cooler
(TEC) with a fan. RAW 264.7 cells were cultured on the sensor
(Fig. 1c1), and infected with MNV-1 (Fig. 1c2); subsequently, the
sensor chip was mounted onto the camera board. As viral pla-
ques appeared and expanded (Fig. 1c3), time-lapse LR images
were recorded: at each frame, the LED array illuminated the
sample from diﬀerent angles, creating a sequence of LR images.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineThe TEC and fan were used to protect the cells and viruses from
the heat generated by the sensor circuit. During the imaging
process, the system was placed inside a standard 37 C CO2
incubator. A laptop running a customized MATLAB program
was used to control the LED array, the TEC, and the fan, as well
as collecting the LR images at 30 min intervals. Aer imaging,
another customized MATLAB super-resolution program pro-
cessed the LR images and produced a HR image for each
imaging interval. A representative, full-FOV HR image is shown
in Fig. 1d with a typical growing plaque (zoomed inset shown in
Fig. 1e). A time-lapse HR image sequence of a growing plaque
compared with the LR images directly captured by the sensor is
shown in Movie S1.†Plaque recognition by image processing
We designed an image-processing program to automatically
detect plaques from time-lapse HR image sequences. This
algorithm is able to detect newly generated plaques, track the
growth of each individual plaque, and distinguish diﬀerent
plaques aer they contact each other. Each frame was processedFig. 2 The plaque recognition algorithm structure.
This journal is © The Royal Society of Chemistry 2014based on the time-lapse HR image sequence using the results of
the previous frames. The program consists of six major steps, as
illustrated by the owchart and representative pictures in Fig. 2.
The dynamic results of these steps are shown in Movie S2.† The
six steps are described in detail as follows:
1. Image loading. A new frame from the HR image
sequence is loaded into the program.
2. Point detection. A brightness threshold is set for the
image (typically 2.2 times the mean value of the whole image),
converting the HR image into a binary (0–1) image with only the
proles of the dying cells. The center-of-mass is extracted from
each prole to generate the dying cell positions into our data
points.
3. Point accumulation. The detected points in step 2 are
combined with the plaque detection results from the previous
frame.
4. Cluster detection. Considering that a plaque is a cluster
of dead cells with high density, we apply a density-based clus-
tering algorithm to the data points generated in step 3. The
DBSCAN algorithm is used.10 This detects clusters by gauging the
spatial density of the points. Briey, each point is evaluated byAnalyst, 2014, 139, 3727–3734 | 3729
Fig. 3 Plaque assay experiment. (a) A six-well plate for the conventional
plaque assay, comparedwith a CMOS image sensor for the ePetri plaque
assay. (b) A representative image of the conventional plaque assay.
Manually counted plaques were labeled with white squares. (c) A
representative image of the ePetri plaque assay (d) with the plaques
automatically detected. (e) The calculated viral titer of the conventional
plaque assay compared with that of the ePetri plaque assay.
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View Article Onlinetwo thresholds. The rst threshold is Eps, which is the required
neighborhood distance between this point and its surrounding
points. The second threshold is MinPnts, which represents the
required number of other points within the Eps neighborhood. If
there are >MinPnts points within the Eps neighborhood, then
this point and all the other points within the Eps neighborhood
are considered elements of the same cluster. In this way, the
algorithm evaluates all the points and labels them according to
the clusters they belong to. The typical values used in our
experiments were Eps ¼ 150 mm and MinPnts ¼ 5.
5. Noise removal. Aer step 4, the points that do not belong
to any cluster are considered noise and are removed from the
current frame.
6. Plaque recognition. The plaque recognition step consists
of several sub-steps. First, each current cluster is compared with
the previously recognized plaques. If it does not have any
common points with previous plaques, it will be considered a
new cluster (this means a new plaque has generated). If it has
common points with only one previous plaque, it will be labeled
the same cluster as the previous one (this means a single plaque
is growing). If it has common points with multiple previous
plaques, these corresponding common points will be labeled
separately according to each previous plaque (this means
multiple plaques are starting to contact each other). Second, each
un-labeled point in the current cluster is assigned to its nearest
labeled cluster. Aer labeling all the points in the current
clusters, each cluster was dened as a recognized plaque.
Aer the last frame is nished, the recognized plaques with
insuﬃcient points (typically <20 points) are considered false
positives and are removed.
We built a customized MATLAB program for this algorithm.
For verication, we manually examined 72 plaques in ve ePetri
plaque assay experiments and compared them with the results
of our program. The plaque recognition accuracy of our
program was 93  7% (there were 3  5% plaques unrecog-
nized, and 2  3% falsely unseparated).ePetri plaque assay
To compare the performance of our ePetri plaque assay method
and the conventional multi-well plate plaque assay, we grew
plaques on both six-well plates and CMOS image sensors
(relative scale shown in Fig. 3a). The RAW 264.7 cells were
cultured to 70% conuence for both groups. The same MNV-1
sample was used with diﬀerent dilutions for each method
(1 : 107 dilution for the conventional plaque assay, and 1 : 105
dilution for the ePetri plaque assay). For the conventional pla-
que assay, cells were stained with neutral red 48 h aer infec-
tion and the plaques were counted by the naked eye (Fig. 3b).
For the ePetri group, the HR images were taken at 30 min
intervals until 32 h aer infection (Fig. 3c) and our plaque
recognition program was used to automatically count the
number of plaques in the last frame (Fig. 3d). The plaque titer
given by the conventional plaque assay and ePetri plaque assay
were 2.1  0.6  108 PFU ml1 (SEM, N ¼ 4) and 1.9  0.3  108
PFU ml1 (SEM, N ¼ 4) respectively, without signicant diﬀer-
ences, according to Student's t-test (P ¼ 0.13) (Fig. 3e). It is3730 | Analyst, 2014, 139, 3727–3734worth noting that we demonstrated a shorter readout time
(32 h) compared with the conventional plaque assay (48 h as
established in the standard protocol1), due to the ability of the
ePetri plaque assay to recognize plaques from their early stages.
We will show this in the next section.Longitudinal observation of plaque growth
In addition to plaque recognition, the ePetri plaque assay
method automatically captures a longitudinal sequence of cell
death events on the entire sensor chip. This means that we can
also use the data to investigate plaque growth dynamics from
their earliest stages. As a demonstration example, we tracked
the growth pattern of a single plaque (Fig. 4). Fig. 4a shows the
time-lapse images of a growing plaque with individual cell
death events labeled. Fig. 4b shows the same plaque with each
cell death event colored according to its occurrence. Based on
these data, we also generated statistics of cell death numbers
over time (Fig. 4c).
Our plaque detection algorithm also gives us the time at
which a new plaque appears. As a demonstration example, we
dened the time of generation of a new plaque as the time at
which it was picked up by our clustering algorithm, and con-
ducted two experiments to monitor plaque formation events
over time (Fig. 5a). From the histogram of the two experimentsThis journal is © The Royal Society of Chemistry 2014
Fig. 4 Longitudinal observation of the plaque growth. (a) Time-lapse
HR images of a growing plaque with individual cell death events
labeled. (b) The same plaque with each cell death event colored
according to its occurrence. (c) Number of cell deaths over time in the
plaque.
Fig. 5 Dynamics of plaque formation. (a) Plaque formation events
over time for two independent experiments. (b and c) The histograms
showing plaque formation distribution in (b) the ﬁrst experiment (green
curve in a) and (c) the second experiment (blue curve in a).
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View Article Online(Fig. 5b and c), we observed that the peak of plaque formation
happened 24–26 h aer MNV-1 infection, and the time between
the formation of early plaques and late plaques was approxi-
mately 6 h.Demonstration study of viral inhibitor treatment
We demonstrated the ePetri device in a viral inhibitor study. We
selected two previously discovered MNV-1 inhibitors. The rst
inhibitor is 20-C-methylcytidine (2CMC), which blocks the RNA
replication pathway.11 The second one is neuraminidase, which
cleaves terminal sialic acids on the surface of host cells, pre-
venting viral attachment to cells.12,13 We included one control
group without inhibitors (Fig. 6a1). We used two diﬀerent
concentrations for the 2CMC treatment group (4 mM and 10 mM)This journal is © The Royal Society of Chemistry 2014and the neuraminidase treatment group (1 mU ml1 and
2.5 mU ml1). Each treatment was repeated once, and a 1 : (2 
104) dilution of a MNV-1 sample was used for all the groups. We
monitored each group for 32 h aer virus infection. To increase
the throughput, we ran 2–3 ePetri devices in parallel each time.
Representative nal plaque recognition results for each group
are shown in Fig. 6a. We then investigated the eﬀects of the two
inhibitors on the total number of plaques (Fig. 6b). In the case
of 2CMC, the plaque number decreased by 40% at a concen-
tration of 4 mM, and no plaques appeared when the concen-
tration increased to 10 mM. In the case of neuraminidase, the
plaque number decreased by 60% at a concentration of 1 mU
ml1, but no further decrease was observed at 2.5 mU ml1.
Further increase in neuraminidase concentration had negative
eﬀects on cell growth. Finally, we also examined the plaque size
by dening the radius of a circle with the same area as the
plaque, calculated the mean and standard deviation of the
radius data for each group, and statistically analyzed the data
between the groups using one-way ANOVA followed by Tukey's
HSD test (Fig. 6c). For the 2CMC group, the plaque radius at 4
mM (106  14 mm, N ¼ 19) was signicantly smaller than that of
the control group (130  15 mm, N ¼ 31) with P < 0.001, and
reduced to 0 mm (no plaques) at 10 mM. For the neuraminidase
group, the plaque radius was also signicantly smaller than the
control group at 1 mUml1 (102  15 mm, N¼ 9) with P < 0.001,
but did not signicantly drop when the dose was increased to
2.5 mU ml1 (95  12 mm, N ¼ 12), with P ¼ 0.677. The results
suggest that 2CMC is capable of completely inhibiting viral
proliferation, whereas neuraminidase is not. In this study, we
added neuraminidase aer viral infection as a proof of concept.
However, as previously studied,12 the treatment of neuramini-
dase before viral infection can have a better inhibitory eﬀect. We
will use our ePetri device to investigate this timing of neur-
aminidase treatment in our future work.
Discussion
The ePetri device has several intrinsic advantages for plaque
analysis. First, its wide FOV supports the observation of
multiple plaques at the same time. Second, its sub-micron
resolution enables much earlier identication of a plaque site
than conventional means, as well as observation of individual
cell death events within each plaque. Third, the imaging
process can be operated automatically and continuously inside
the incubator. This not only saves labor and avoids disturbing
the sample, but also allows the monitoring of the plaque growth
process. Fourth, the ePetri device is engineered using mass-
producible electronic components without optical lenses,
making it a low-cost imaging solution. Finally, the ePetri device
is compact in size (10  10  10 cm3 for our current prototype)
and allowsmultiple devices to be run in parallel inside the same
incubator, increasing imaging throughput.
In this study, we selectedMNV-1 as our virus model due to its
high signicance. Norovirus (NoV) is the top pathogen causing
foodborne illness in the United States and is responsible for
more than 23million infections per year.14 So far, little is known
about the infectionmechanisms of human NoVs and there is noAnalyst, 2014, 139, 3727–3734 | 3731
Fig. 6 Study of viral inhibitor treatments. (a1–a5) Representative images showing the plaque recognition results of (a1) the control group, the
2CMC group at concentrations of (a2) 4 mM, and (a3) 10 mM, and the neuraminidase group at concentrations of (a4) 1 mU ml1 and (a5) 2.5 mU
ml1, 32 h after MNV-1 infection. (b) Number of plaques for all the ﬁve groups. (c) Means and standard deviations of the plaque radii for all the ﬁve
groups (*P < 0.05).
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View Article Onlinespecic treatment for human NoV infection because it cannot
grow in tissue culture systems. Discovered in 2003, MNV-1 is the
only member of NoVs that can successfully grow in tissue
culture.15 We believe that the ePetri approach can provide more
insight into the mechanisms of NoV infection, as well as those
of other viruses that are conventionally studied by plaque
assays.
We used thresholding to detect virus-induced cell death
events in our algorithm. Occasionally, some random cell deaths
or temporary cell detachment events (such as cell division) were
also picked up by the thresholding. These data points are
considered noise for plaque detection. These noise points are
randomly generated and sparsely distributed around the whole
imaging area. Conversely, the cell deaths inside virus plaques
have much higher density; therefore, we were able to extract
them from the noise by applying the density-based clustering
algorithm.
We measured the virus concentration of the same sample
using both the ePetri plaque assay and the conventional plaque
assay in a 6-well plate. We were able to read out the results using
the ePetri plaque assay at 32 h aer infection, whereas we read
out the conventional plaque assay by the naked eye 48 h aer
infection, following standard protocols.1 The ePetri plaque3732 | Analyst, 2014, 139, 3727–3734assay provides high resolution in detecting single cell death
events; therefore, we were able to recognize plaques when they
were still small in size, reducing the wait time for the plaque
assay.
We determined the formation time of a plaque by looking at
when a cluster was recognized by our algorithm. The experi-
ment shows that the peak of plaque formation occurred at
24–26 h aer infection, and the time between the formation of
early plaques and late plaques was 6 h. This veries that the
32 h monitoring time was enough to cover the formation events
of all the plaques. The 6 h diﬀerence between the early and
late plaques may suggest the heterogeneous nature of our virus
sample. This contains rich information on viral behavior and is
worth further investigation. One future experiment might
involve retrieving the virus from a single plaque and testing
whether the plaque formation time can be synchronized.
Another would be to work on diﬀerent virus strains and study
the variation in their plaque formation time.
Generally, there are ve steps in a virus life cycle: attachment
to the host cell membrane, entry into the cell, genome replica-
tion, protein synthesis, and virus release.16 In this study, we
demonstrated the application of our system on the evaluation of
antiviral drugs by choosing two already established virusThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineinhibitors: neuraminidase and 2CMC, which inhibit the
membrane attachment and RNA replication, respectively, of
MNV-1. In recent years, many other antiviral drugs targeting
diﬀerent steps of the virus life cycle have also been studied. For
example, dynasore and nocodazole were reported to inhibit
virus entry.17 WP1130, ribavirin, and simvastatin were reported
to suppress virus replication.18–20 Cycloheximide and type I/II
interferons inhibit virus protein synthesis.21,22 Oseltamivir and
zanamivir inhibit virus release from host cells.16 The ePetri is a
potential powerful tool for studying all these drugs and their
eﬀects on plaque formation and plaque growth dynamics.
The conventional plaque assay has several inherent limita-
tions. First, it is time-consuming because plaque growth is a
slow process and can take several days. Second, many viruses do
not kill host cells and consequently do not form plaques;
therefore, it is not possible to study them using the plaque
assay. To overcome these limitations, a variation of the plaque
assay called the uorescent focus assay (FFA) was developed.23 A
FFA is similar to a plaque assay except that it uses uorescently
labeled antibodies targeting viral antigens to measure host cell
infection; therefore, it can give information on viral spread even
before a plaque is formed. In addition, such an assay can
directly visualize viruses, so that plaque observation is not
needed. We have recently developed a wide FOV on-chip uo-
rescencemicroscope that supports high-resolution uorescence
imaging, and have already demonstrated its use in time-lapse
imaging of GFP-labeled HeLa cells as well as in the study of anti-
cancer drugs.24,25 We believe this uorescence ePetri device will
be well-suited for the study of FFA in our future work.
Conclusion
In this work we applied the ePetri device to viral plaque analysis.
Time-lapse, high-resolution images were obtained by the ePetri
device at 30 min intervals. A density-based clustering algorithm,
DBSCAN, was introduced into a customized program for plaque
recognition. This plaque recognition program was then used for
the plaque assay and longitudinal monitoring of plaque
formation and growth. We further explored potential applica-
tions of our device by studying the two viral inhibitors, 2CMC
and neuraminidase, and observed a diﬀerence in their inhibi-
tion on plaque growth. We expect that the ePetri device can be
used for many applications such as the study of virus behavior
and the discovery of new antiviral drugs.
Experimental section
Conventional plaque assay
Conventional plaque assays were conducted by the following
standard protocols.1 Briey, RAW 264.7 cells (70% conuency)
cultured in DMEM were inoculated with various dilutions of the
MNV-1 sample in six-well plates with each dilution added in two
wells (0.5 ml per well). Aer 1.5 h incubation for MNV-1
attachment, the media was removed and a 37 C low melting
point agarose solution (1.5% in DMEM, 3 ml per well) was
added. The plates were placed into a 37 C CO2 incubator for
48 h, then stained with 0.02% neutral red solution for 1 h.This journal is © The Royal Society of Chemistry 2014Visible plaques were counted by the naked eye. The number of
plaques in both wells at each dilution were added and multi-
plied by the dilution factor. This gives the number of plaque
forming units (PFUs) in a 1 ml volume. For example, consider
two wells at 1 : 107 dilution, if one well has 10 plaques and
the other well has 5 plaques, the viral titer is 10  107 + 5 
107 ¼ 15  107 PFU ml1.The ePetri device for plaque analysis
The ePetri device was designed based on our previous work8 and
provided by ePetri Inc. We used MT9P031 (2.2 mm pixel, Aptina)
for the image sensors and removed their microlens layers by
treating them in oxygen plasma for 10 min at 80 W. The
homemade square plastic reservoir was glued to the image
sensor using polydimethylsiloxane (PDMS).
The protocol for viral plaque growth on the image sensor is
similar to that used in the conventional plaque assay. Briey,
image sensors were pre-treated with trypsin for surface
cleaning and better cell adhesion. The DMEM solution con-
taining 105 RAW 264.7 cells was lled into each sensor's
reservoir. Aer cells grew to 70% conuence, the media
was changed to the diluted MNV-1 solution (typically 20 ml)
and a coverslip was placed on top of the medium. Aer 1.5 h
incubation for MNV-1 attachment, the coverslip and virus
solution were removed, and the 37 C low-melting point
agarose solution (1.5% in DMEM, 150 ml) was added. A thin
layer of DMEM was overlaid on top of the agarose to prevent
evaporation. Sensor chips were mounted onto the ePetri
devices with a customized PDMS cap placed above the image
sensor to prevent further evaporation. The systems were
placed into the 37 C CO2 incubator for continuous imaging
(30 min intervals).
The viral titer for the ePetri plaque assay was calculated in a
similar manner to the conventional plaque assay. However,
because the reservoir's area (7.25 7.25 mm2) was 2.15 times of
the sensor's imaging area (5.70  4.28 mm2), the measured
virus concentration was multiplied by this factor during calcu-
lations. For example, consider we use 20 ml MNV-1 solution at
1 : 105 dilution, if we count 15 plaques, then the viral titer is
15 O 0.02  105  2.15 ¼ 16  107 PFU ml1.
For the experiments in the viral inhibitor study, the protocol
remained the same, except that the drug (2CMC/neuramini-
dase) was added to the low-melting point agarose solution
before it was overlaid onto the cells.Acknowledgements
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